GSTC

AngioSoma Inc

GSTC, USA

GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, engages in the provision of patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases in the United States. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in New York, New York.

https://www.globestartherapeutics.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
GSTC
stock
GSTC

How Greece Can Better Manage Tourism, According to GSTC CEO tovima.com

Read more →
GSTC
stock
GSTC

Istanbul crowned Europe’s most desirable city at 2025 Wanderlust Travel Awards Türkiye Today

Read more →

Showing 2 of 10

Finn Analysis

(Last Updated 2024-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.07

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Low

12.19 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-236.07 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 0.00% of the total shares of AngioSoma Inc

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2024-09-30

EPS Actual

0

EPS Estimate

0

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2024-09-30)

Deep Value
Weak Deep Value(1)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(1.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2024-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2024-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2024-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.